A1C went from 7.4 to 5.6 over nine months and my prescriber was more interested in the fasting insulin, which I did not expect.
Because it is glucose-dependent, this class carries a low intrinsic hypoglycaemia risk on its own — the risk arrives when it is combined with insulin or a sulfonylurea, which usually need reducing.
What I actually want to know is why A1C lags the way it does, and what to look at in the meantime if you want to know sooner.
I have searched first, so if this is covered somewhere point me at it and I will read it.
MariaRD said:A1C went from 7.4 to 5.6 over nine months and my prescriber was more interested in the fasting insulin, which I did not expect.
My labs after 3 months on glycaemic control: A1C 5.6%, fasting glucose 91 mg/dL, fasting insulin 4 uIU/mL. My endo says these are "textbook perfect."
For context, my baseline A1C was 7.7% and fasting glucose was 116 mg/dL. The improvement has been dramatic and consistent.
TrialTracker_MD said:My labs after 3 months on glycaemic control: A1C 5.6%, fasting glucose 91 mg/dL, fasting insulin 4 uIU/mL.
Insulin sensitivity test (HOMA-IR) on glycaemic control — arguably the most important metabolic marker most people aren't tracking:
HOMA-IR = (fasting insulin × fasting glucose) ÷ 405
My numbers: Baseline HOMA-IR = 4.3 (insulin resistant) → Current = 1.1 (insulin sensitive)
Anything above 2.0 indicates insulin resistance. The goal is below 1.5. GLP-1 agonists address the root metabolic dysfunction, not just the symptoms. This is why they work so much better than calorie restriction alone.
Sigma-Aldrich — Research-Grade Standards
Certified reference materials, analytical reagents, and research-grade standards for peptide verification. Trusted by laboratories worldwide.
Shop Reference StandardsMariaRD said:A1C went from 7.4 to 5.6 over nine months and my prescriber was more interested in the fasting insulin, which I did not expect.
Mine went the same way, slower.
Clinical perspective, offered as context rather than as advice.
Complete metabolic panel trending on glycaemic control — sharing because comprehensive data helps everyone:
| Test | Baseline | Month 3 | Month 6 | Month 12 |
|---|---|---|---|---|
| Glucose (fasting) | 117 | 103 | 89 | 87 |
| Insulin (fasting) | 23 | 17 | 9 | 7 |
| HOMA-IR | 5.5 | 3.3 | 1.7 | 1.1 |
| Uric Acid | 8.0 | 6.7 | 5.6 | 4.8 |
The insulin resistance improvement (HOMA-IR) is what my endo focuses on most. Going from 5.5 to near 1.0 is a metabolic transformation.